Literature DB >> 24311613

High-density lipoprotein: NO failure in heart failure.

Ali Javaheri1, Daniel J Rader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24311613      PMCID： PMC4111252          DOI： 10.1161/CIRCRESAHA.113.302667

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  33 in total

1.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase.

Authors:  I S Yuhanna; Y Zhu; B E Cox; L D Hahner; S Osborne-Lawrence; P Lu; Y L Marcel; R G Anderson; M E Mendelsohn; H H Hobbs; P W Shaul
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality.

Authors:  Amit V Khera; Parin J Patel; Muredach P Reilly; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2013-08-07       Impact factor: 24.094

3.  Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation.

Authors:  A Blair; P W Shaul; I S Yuhanna; P A Conrad; E J Smart
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

4.  Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.

Authors:  Volker Adams; Christian Besler; Tina Fischer; Meliana Riwanto; Friederike Noack; Robert Höllriegel; Andreas Oberbach; Nico Jehmlich; Uwe Völker; Ephraim B Winzer; Karsten Lenk; Rainer Hambrecht; Gerhard Schuler; Axel Linke; Ulf Landmesser; Sandra Erbs
Journal:  Circ Res       Date:  2013-09-20       Impact factor: 17.367

5.  10-year exercise training in chronic heart failure: a randomized controlled trial.

Authors:  Romualdo Belardinelli; Demetrios Georgiou; Giovanni Cianci; Augusto Purcaro
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

6.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

7.  Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.

Authors:  Thimoteus Speer; Lucia Rohrer; Przemyslaw Blyszczuk; Rukshana Shroff; Kira Kuschnerus; Nicolle Kränkel; Gabriela Kania; Stephen Zewinger; Alexander Akhmedov; Yi Shi; Tina Martin; Damir Perisa; Stephan Winnik; Maja F Müller; Urban Sester; Gabriel Wernicke; Andreas Jung; Ursula Gutteck; Urs Eriksson; Jürgen Geisel; John Deanfield; Arnold von Eckardstein; Thomas F Lüscher; Danilo Fliser; Ferdinand H Bahlmann; Ulf Landmesser
Journal:  Immunity       Date:  2013-03-07       Impact factor: 31.745

8.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

9.  Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis.

Authors:  Nehal N Mehta; Ron Li; Parasuram Krishnamoorthy; YiDing Yu; William Farver; Amrith Rodrigues; Anna Raper; Mackenzie Wilcox; Amanda Baer; Stephanie DerOhannesian; Megan Wolfe; Muredach P Reilly; Daniel J Rader; Abby VanVoorhees; Joel M Gelfand
Journal:  Atherosclerosis       Date:  2012-07-21       Impact factor: 5.162

10.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Authors: 
Journal:  Eur Heart J       Date:  2013-02-26       Impact factor: 29.983
View more
  1 in total

1.  Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure.

Authors:  Ephraim B Winzer; Pauline Gaida; Robert Höllriegel; Tina Fischer; Axel Linke; Gerhard Schuler; Volker Adams; Sandra Erbs
Journal:  Cardiol Res Pract       Date:  2016-08-02       Impact factor: 1.866
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.